Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YTHDC1 | Q96MU7 | 5/20 | 0.53 |
| ▸ | CDK1 | P06493 | 2/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.48 |
| ▸ | CTSL | P07711 | 3/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17628588 | 0.86 | CDK1 (0.70) | YTHDC1CDK1ADORA2AADORA1ADORA3 | |
| SCHEMBL19763769 | 0.85 | YTHDC1 (0.54) | YTHDC1CDK1ADORA2AADORA1CCNA2 | |
| SCHEMBL6821052 | 0.84 | YTHDC1 (0.53) | YTHDC1CDK1ADORA2AADORA1CCNA2 | |
| SCHEMBL6817859 | 0.84 | CDK1 (0.74) | YTHDC1CDK1ADORA2AADORA1CCNA2 | |
| SCHEMBL17628580 | 0.82 | TMIGD3 (0.70) | YTHDC1CDK1ADORA2AADORA1CCNA2 | |
| SCHEMBL17628619 | 0.81 | YTHDC1 (0.57) | YTHDC1CDK1ADORA2AADORA1CCNA2 | |
| SCHEMBL17628578 | 0.80 | CDK1 (0.65) | YTHDC1CDK1ADORA2AADORA1CCNA2 | |
| SCHEMBL17628625 | 0.79 | CDK2 (0.78) | CDK1CCNA2CDK2CCNA1CACNA1B | |
| SCHEMBL17628627 | 0.79 | CDK2 (0.78) | CDK1CCNA2CDK2CCNA1CACNA1B | |
| SCHEMBL6817839 | 0.78 | HDAC1 (0.67) | YTHDC1ADORA2AADORA1TMIGD3CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752629-B2 | Calcium channel agonists | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190084984-A1 | CALCIUM CHANNEL AGONISTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-03-21 | — | — | US | disclosed |
| US-10174031-B2 | Calcium channel agonists | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180009810-A1 | CALCIUM CHANNEL AGONISTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-01-11 | — | — | US | disclosed |
| US-9796714-B2 | Calcium channel agonists | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-10-24 | — | — | US | disclosed |
| US-20160090387-A1 | CALCIUM CHANNEL AGONISTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009810-A1 | CALCIUM CHANNEL AGONISTS | CACNA1E, CACNA1C, CACNA1S | YTHDC1 3460/4885CDK1 2530/4885ADORA2A 601/4885 |
| US-20190084984-A1 | CALCIUM CHANNEL AGONISTS | CACNA1E, CACNA1C, CACNA1S | YTHDC1 3460/4885CDK1 2530/4885ADORA2A 601/4885 |
| US-20160090387-A1 | CALCIUM CHANNEL AGONISTS | CACNA1E, CACNA1C, CACNA1S | YTHDC1 3460/4885CDK1 2530/4885ADORA2A 601/4885 |
| US-10174031-B2 | Calcium channel agonists | CACNA1E, CACNA1C, CACNA1S | YTHDC1 3460/4885CDK1 2530/4885ADORA2A 601/4885 |
| US-10752629-B2 | Calcium channel agonists | CACNA1E, CACNA1C, CACNA1S | YTHDC1 3460/4885CDK1 2530/4885ADORA2A 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.